Comparison of Long-Term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Na ïve Patients with Ulcerative Colitis.

Conclusions: In our study, infliximab and adalimumab had similar treatment efficacy and long-term outcomes in biologic-naïve patients with moderate to severe UC.
PMID: 32616683 [PubMed - as supplied by publisher]

Source: Gut and Liver - July 5, 2020 Category: Gastroenterology Tags: Gut Liver Source Type: research